Management of cutaneous rosacea: emphasis on new medical therapies

被引:10
作者
Del Rosso, James Q. [1 ]
机构
[1] Touro Univ, Coll Osteopath Med, Henderson, NV 89014 USA
关键词
brimonidine gel; centrofacial erythema; ivermectin; rosacea; topical alpha-agonists; TARTRATE GEL 0.5-PERCENT; SEVERE FACIAL ERYTHEMA; ACID 15-PERCENT GEL; SUBANTIMICROBIAL-DOSE DOXYCYCLINE; SERINE-PROTEASE ACTIVITY; RANDOMIZED PHASE-III; PAPULOPUSTULAR ROSACEA; CONSENSUS RECOMMENDATIONS; AMERICAN ACNE; ERYTHEMATOTELANGIECTATIC ROSACEA;
D O I
10.1517/14656566.2014.945423
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Over the past decade, both basic science and clinical research have provided new information on pathophysiology and therapy that has led to advances in the management of rosacea. As rosacea is a very common facial skin disorder in adults of both genders and essentially all races and ethnicities, these advances can provide therapeutic benefit to many affected individuals around the world. Areas covered: This article provides a collective review of more recent information on the pathophysiology and clinical manifestations of rosacea, and discusses individual medical therapies based on PubMed literature searches on 'rosacea', 'rosacea therapies' and each therapy that are included in this article. The perspectives of the author on management of rosacea are also included. Newer therapies and treatment concepts received greater emphasis. Expert opinion: Management of cutaneous rosacea involves patient education, integration of proper skin care, differentiation of visible manifestations and symptoms, selecting therapies that correlate with the manifestations that are to be treated, setting realistic patient expectations on anticipated degree and time course of response and designing an overall management plan that addresses needs of the individual patient. In many cases, a combination approach is needed, and due to the chronicity of the disease long-term management is often warranted.
引用
收藏
页码:2029 / 2038
页数:10
相关论文
共 78 条
[1]   A study of the pathogenesis of Rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process [J].
Aroni, Kyriaki ;
Tsagroni, Eugenia ;
Kavantzas, Nikolaos ;
Patsouris, Efstratios ;
Ioannidis, Eleftherios .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2008, 300 (03) :125-131
[2]   Therapeutic potential of azithromycin in rosacea [J].
Bakar, Ö ;
Demirçay, Z ;
Gürbüz, O .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2004, 43 (02) :151-154
[3]   Rosacea: Current thoughts on origin [J].
Bamford, JTM .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2001, 20 (03) :199-206
[4]   Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea [J].
Benkali, K. ;
Leoni, M. ;
Rony, F. ;
Bouer, R. ;
Fernando, A. ;
Graeber, M. ;
Wagner, N. .
BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (01) :162-169
[5]  
Bhatia ND, 2012, J DRUGS DERMATOL, V11, P838
[6]  
Bikowski Joseph B, 2003, Skinmed, V2, P234
[7]  
Carney CK, 2009, GIORN ITAL DERMAT V, V144, P673
[8]   Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation [J].
Casas, Christiane ;
Paul, Carle ;
Lahfa, Morad ;
Livideanu, Bulai ;
Lejeune, Ophelie ;
Alvarez-Georges, Sandrine ;
Saint-Martory, Christine ;
Degouy, Arnaud ;
Mengeaud, Valerie ;
Ginisty, Herve ;
Durbise, Elizabeth ;
Schmitt, Anne M. ;
Redoules, Daniel .
EXPERIMENTAL DERMATOLOGY, 2012, 21 (12) :906-910
[9]   Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel [J].
Coda, Alvin B. ;
Hata, Tissa ;
Miller, Jeremiah ;
Audish, David ;
Kotol, Paul ;
Two, Aimee ;
Shafiq, Faiza ;
Yamasaki, Kenshi ;
Harper, Julie C. ;
Del Rosso, James Q. ;
Gallo, Richard L. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (04) :570-577
[10]  
Conde Jennifer F, 2007, J Drugs Dermatol, V6, P495